TheStreet lowered shares of Cryolife (NYSE:CRY) from a c- rating to a d+ rating in a research report report published on Friday morning, TheStreetRatingsTable reports.
Several other research analysts also recently weighed in on the stock. ValuEngine raised shares of Cryolife from a hold rating to a buy rating in a research report on Friday, March 20th. Needham & Company LLC began coverage on shares of Cryolife in a research report on Tuesday, June 30th. They issued a buy rating and a $29.00 target price on the stock. Oppenheimer dropped their target price on shares of Cryolife from $34.00 to $25.00 in a research report on Thursday, April 2nd. Zacks Investment Research downgraded shares of Cryolife from a buy rating to a hold rating in a research report on Thursday, July 2nd. Finally, Lake Street Capital lifted their target price on shares of Cryolife from $22.00 to $27.00 and gave the stock a buy rating in a research report on Friday, May 1st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Cryolife presently has a consensus rating of Buy and a consensus target price of $26.20.
NYSE CRY opened at $18.37 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.90 and a quick ratio of 3.66. The company’s 50 day simple moving average is $21.22 and its 200 day simple moving average is $23.39. Cryolife has a 12 month low of $12.63 and a 12 month high of $33.00. The company has a market capitalization of $688.76 million, a P/E ratio of -141.31 and a beta of 1.37.
Cryolife (NYSE:CRY) last released its earnings results on Thursday, April 30th. The medical equipment provider reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.10). Cryolife had a positive return on equity of 2.55% and a negative net margin of 1.69%. The business had revenue of $66.43 million during the quarter, compared to the consensus estimate of $66.11 million. During the same quarter in the previous year, the firm earned $0.04 earnings per share. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, analysts anticipate that Cryolife will post -0.17 earnings per share for the current year.
In related news, Director Ronald D. Mccall sold 1,719 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $22.82, for a total transaction of $39,227.58. Following the transaction, the director now directly owns 127,766 shares of the company’s stock, valued at $2,915,620.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.70% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Prudential Financial Inc. grew its position in Cryolife by 1.0% in the fourth quarter. Prudential Financial Inc. now owns 63,317 shares of the medical equipment provider’s stock worth $1,715,000 after acquiring an additional 633 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Cryolife by 37.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,093 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 848 shares in the last quarter. Swiss National Bank grew its position in Cryolife by 1.4% in the first quarter. Swiss National Bank now owns 72,700 shares of the medical equipment provider’s stock worth $1,230,000 after acquiring an additional 1,000 shares in the last quarter. Victory Capital Management Inc. grew its position in Cryolife by 7.1% in the first quarter. Victory Capital Management Inc. now owns 17,913 shares of the medical equipment provider’s stock worth $303,000 after acquiring an additional 1,184 shares in the last quarter. Finally, Comerica Bank grew its position in Cryolife by 3.4% in the first quarter. Comerica Bank now owns 36,392 shares of the medical equipment provider’s stock worth $766,000 after acquiring an additional 1,185 shares in the last quarter. 81.91% of the stock is owned by institutional investors.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
See Also: Fibonacci Channel
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.